Report Overview:
Therapeutic Monoclonal Antibodies (MABs) are a class of biologic drugs designed to target specific molecules in the body, primarily for treating diseases like cancer, autoimmune disorders, and infectious diseases. These drugs are engineered to bind to specific proteins or antigens on the surface of cells, disrupting disease progression or enhancing the immune response. Monoclonal antibodies are derived from a single clone of cells, which allows for the creation of drugs that are highly specific to the targeted antigen.
In the context of oncology, monoclonal antibodies are used to treat various cancers by either marking cancer cells for destruction by the immune system or directly interfering with the mechanisms that allow cancer cells to proliferate. These therapies have revolutionized the treatment of diseases like lymphoma, breast cancer, and colorectal cancer, offering targeted treatment with fewer side effects compared to traditional chemotherapy.
Market Value:
The global Therapeutic Monoclonal Antibodies Drug market was valued at USD 162.41 billion in 2024 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.00% from 2024 to 2032, reaching an estimated USD 374.27 billion by the end of the forecast period. CAGR of 11.00% (2025 – 2032)
By Types:
• Mouse-derived Antibodies
• Chimeric Antibodies
• Humanized Antibodies
By Applications: Immune Diseases Cancer
Key players include:
• AbbVie
• Johnson & Johnson
• Novartis
• Gilead Sciences
• Roche
• Bristol-Myers Squibb
• Amgen
• AstraZeneca
• Merck & Co
• TakedaIncluding or Excluding key companies relevant to your analysis.
www.statsmarketresearch.com
